Medifast Inc (NYSE:MED - Get Free Report) Director Parsa Kiai acquired 85,150 shares of the stock in a transaction that occurred on Thursday, November 19th. The stock was purchased at an average price of $12.05 per share, with a total value of $1,026,057.50. Following the transaction, the director owned 804,221 shares in the company, valued at $9,690,863.05. This represents a 11.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Parsa Kiai also recently made the following trade(s):
- On Wednesday, November 18th, Parsa Kiai acquired 8,886 shares of Medifast stock. The shares were purchased at an average price of $12.16 per share, with a total value of $108,053.76.
- On Wednesday, November 4th, Parsa Kiai purchased 661 shares of Medifast stock. The shares were purchased at an average cost of $13.03 per share, for a total transaction of $8,612.83.
- On Wednesday, October 28th, Parsa Kiai purchased 5,557 shares of Medifast stock. The stock was acquired at an average cost of $12.24 per share, with a total value of $68,017.68.
- On Wednesday, August 26th, Parsa Kiai purchased 43,150 shares of Medifast stock. The shares were acquired at an average price of $12.26 per share, for a total transaction of $529,019.00.
- On Monday, August 24th, Parsa Kiai acquired 4,329 shares of Medifast stock. The stock was acquired at an average price of $12.00 per share, with a total value of $51,948.00.
Medifast Stock Down 1.9%
Shares of NYSE:MED traded down $0.23 during midday trading on Friday, hitting $11.75. 107,868 shares of the stock traded hands, compared to its average volume of 200,250. Medifast Inc has a one year low of $9.22 and a one year high of $13.63. The stock has a market capitalization of $131.33 million, a PE ratio of -3.18 and a beta of 0.65. The business's 50 day moving average is $12.15 and its two-hundred day moving average is $11.41.
Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings data on Monday, October 26th. The specialty retailer reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.16. Medifast had a negative return on equity of 6.90% and a negative net margin of 13.64%. The company had revenue of $72.05 million during the quarter, compared to analyst estimates of $71.30 million. As a group, sell-side analysts forecast that Medifast Inc will post -0.52 earnings per share for the current year.
Hedge Funds Weigh In On Medifast
Hedge funds and other institutional investors have recently made changes to their positions in the business. American Century Companies Inc. increased its position in Medifast by 37.7% in the third quarter. American Century Companies Inc. now owns 439,221 shares of the specialty retailer's stock worth $5,060,000 after buying an additional 120,310 shares during the period. BlackRock Inc. acquired a new position in shares of Medifast during the second quarter valued at $3,920,000. Dimensional Fund Advisors LP boosted its holdings in shares of Medifast by 10.9% during the first quarter. Dimensional Fund Advisors LP now owns 361,762 shares of the specialty retailer's stock valued at $3,686,000 after acquiring an additional 35,522 shares during the period. Marshall Wace LLP boosted its holdings in shares of Medifast by 46.0% during the third quarter. Marshall Wace LLP now owns 352,704 shares of the specialty retailer's stock valued at $4,063,000 after acquiring an additional 111,055 shares during the period. Finally, Commons Capital LLC grew its position in shares of Medifast by 23.0% during the third quarter. Commons Capital LLC now owns 184,432 shares of the specialty retailer's stock worth $2,125,000 after acquiring an additional 34,516 shares during the last quarter. Institutional investors and hedge funds own 95.51% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Weiss Ratings lowered shares of Medifast from a "sell (d)" rating to a "sell (d-)" rating in a report on Wednesday, October 28th. Zacks Research cut shares of Medifast from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 11th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Medifast has a consensus rating of "Reduce" and a consensus price target of $12.00.
Check Out Our Latest Stock Analysis on MED
About Medifast
(
Get Free Report)
Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company's approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company's programs.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.